med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

373
active users

#peptide

0 posts0 participants0 posts today

Very nice presentation on ligandomics-based treatment selection for personalized vaccination approaches. Prof Juliane Waltz summarised the state-of-the-art...with adjuvant application for #peptide or #mrna vaccines in #Oncology being the current field with promising results. #Immunotherapy combinations bring up the questions: when? What target? And so on... Plenty of aspects to explore! Immunotherapy of cancer conference #ITOC11 #immunology #science #health

Mutation-Tolerant

SARS-CoV-2 Inhibitor Peptide

February 08, 2025 • (S3 E3 )

CESPES isn't just a potential COVID treatment. It's a blueprint for a more sophisticated approach to understanding complex systems.

#COVID19 #Peptide

EPISODE LINKS

buzzSprout
buzzsprout.com/2405788/episode

substack
open.substack.com/pub/helioxpo

Heliox Podcast
( please subscribe, follow, like ". )

episodes.fm/1769969487
patreon.com/c/HelioxPodcast

youtube.com/channel/UCd5BbCEeC

helioxpodcast.substack.com/pub

Oral insulin drops developed by B.C. researchers | CTV News bc.ctvnews.ca/game-changer-b-c “Dr. Shyh-Dar Li's team at UBC has developed oral drops that can be placed under the tongue.

.. his team began developing the option about three years ago, explaining the drops have a mixture of and a unique cell-penetrating , which helps the dose reach the bloodstream. Without that peptide, the insulin can remain stuck in the lining of the mouth,”

British Columbia · 'Game changer': B.C. researchers developing oral insulin drops for diabetes patientsResearchers at the University of British Columbia have developed a needle-free method for people with diabetes to control their blood glucose levels, which could change the way people manage the disease.

A recently developed ⭐#cancer #vaccine for dogs⭐️ is showing promising results in clinical trials, which have been running since 2016, and there's hope that some of the benefits of the vaccine could be translated into human cancer treatments.

More than 300 dogs have been treated with the vaccine to date, and the twelve--month survival rate for canines with certain cancers has been lifted from about 35 percent to 60 percent. Tumors in many of the animals have also shrunk.

Known officially as the #Canine #EGFR/#HER2 #Peptide #Cancer #Immunotherapeutic, the treatment grew out of studies of autoimmune diseases, where the immune system damages the body's own tissue rather than any invading threats.
The vaccine is designed to get the immune system to attack cancer instead.

In many ways tumors are like the targets of autoimmune diseases," says rheumatologist #Mark #Mamula, from the Yale University School of Medicine.

"Cancer cells are your own tissue and are attacked by the immune system. The difference is we want the immune system to attack a tumor."

As outlined in a 2021 study by Mamula and colleagues, the treatment gets the immune cells to produce antibody defenses, which attach themselves to tumors and interfere with their growth patterns.

Specifically, these antibodies hunt down two proteins: 🔸epidermal growth factor receptor 🔸( #EGFR ) and 🔸human epidermal growth factor receptor 2🔸 ( #HER2 ).

Mutations causing overexpression of these proteins drive uncontrolled cell division in some human and canine cancers.

sciencealert.com/breakthrough-

ScienceAlert · Breakthrough Cancer Vaccine For Dogs Is 'Truly Revolutionary', Scientist SaysA recently developed cancer vaccine for dogs is showing promising results in clinical trials, which have been running since 2016, and there's hope that some of the benefits of the vaccine could be translated into human cancer treatments.
BioMed CentralA snake venom-analog peptide that inhibits SARS-CoV-2 and papain-like protease displays antithrombotic activity in mice arterial thrombosis model, without interfering with bleeding time - Thrombosis JournalBackground (p-BthTX-I)2 K, a dimeric analog peptide derived from the C-terminal region of phospholipase A2-like bothropstoxin-I (p-BthTX-I), is resistant to plasma proteolysis and inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains with weak cytotoxic effects. Complications of SARS-CoV-2 infection include vascular problems and increased risk of thrombosis; therefore, studies to identify new drugs for treating SARS-CoV-2 infections that also inhibit thrombosis and minimize the risk of bleeding are required. Objectives To determine whether (p-BthTX-I)2 K affects the hemostatic system. Methods Platelet aggregation was induced by collagen, arachidonic acid, and adenosine diphosphate (ADP) in the Chronolog Lumi-aggregometer. The coagulation activity was evaluated by determining activated partial thromboplastin clotting time (aPTT) and prothrombin time (PT) with (p-BthTX-I)2 K (5.0–434.5 µg) or 0.9% NaCl. Arterial thrombosis was induced with a 540 nm laser and 3.5–20 mg kg− 1 Rose Bengal in the carotid artery of male C57BL/6J mice using (p-BthTX-I)2 K. Bleeding time was determined in mouse tails immersed in saline at 37 °C after (p-BthTX-I)2 K (4.0 mg/kg and 8.0 mg/kg) or saline administration. Results (p-BthTX-I)2 K prolonged the aPTT and PT by blocking kallikrein and FXa-like activities. Moreover, (p-BthTX-I)2 K inhibited ADP-, collagen-, and arachidonic acid-induced platelet aggregation in a dose-dependent manner. Further, low concentrations of (p-BthTX-I)2 K extended the time to artery occlusion by the formed thrombus. However, (p-BthTX-I)2 K did not prolong the bleeding time in the mouse model of arterial thrombosis. Conclusion These results demonstrate the antithrombotic activity of the peptide (p-BthTX-I)2 K possibly by kallikrein inhibition, suggesting its strong biotechnological potential.